CEO Executive AssistantNamed Patient Programs and compassionate use frameworks outside of formal expanded access programs create a set of obligations for pharmaceutical CEOs that are simultaneously humanitarian, regulatory, commercial, and ethical. Patients who have exhausted standard treatment options and whose physicians believe an investigational or unapproved medicine may provide meaningful benefit represent a specific type of access demand that pharmaceutical companies are expected to manage thoughtfully and consistently.
In European markets, where named patient programs and compassionate use frameworks are more extensively developed than in the United States, the CEO’s governance responsibilities extend across country-by-country regulatory requirements, safety data collection and pharmacovigilance reporting, patient and physician communication, and the ethical framework that governs which patients are eligible and under what circumstances access is provided.
Pharma CEO named patient program time management is primarily a governance challenge, not an operational one. The operations of an NPP, including physician applications, drug supply logistics, and safety data collection, are managed by the medical affairs and pharmacovigilance organizations. The CEO’s role is to set the ethical framework, govern the program boundaries, and ensure that safety data from NPP patients flows appropriately into the pharmacovigilance system.
The European NPP Landscape: Country-by-Country Variation
Named Patient Programs in Europe operate under varying national regulatory frameworks. Directive 2001/83/EC provides the EU legal basis for compassionate use programs, but implementation is largely at the member state level, creating meaningful country-by-country variation in program requirements, approval timelines, and safety reporting standards.
Germany. German Heilmittelwerbegesetz and Arzneimittelgesetz provisions allow named patient supply of unapproved medicines on a physician request basis. The Paul Ehrlich Institute regulates biological medicines supplied under named patient frameworks. Safety reports from named patient programs must be integrated into the company’s pharmacovigilance system.
France. France has both a compassionate use framework (Autorisation Temporaire d’Utilisation, ATU, recently updated to Accès Précoce under the LFSS 2021 reform) and a named patient supply pathway. The ATU/Accès Précoce framework is more formalized and provides temporary authorization for specific indications; named patient supply is available for individual cases. ANSM oversight of these programs is active and the reporting requirements are substantive.
United Kingdom. Post-Brexit, the UK operates its own named patient supply framework under MHRA oversight. The Early Access to Medicines Scheme (EAMS) provides a formal route for patients to access promising medicines before authorization. Named patient supply is available outside EAMS for individual physician requests.
Spain and Italy. Both markets have active named patient frameworks with national regulatory agency oversight (AEMPS in Spain, AIFA in Italy). These markets are among the most active for pre-approval compassionate use in Europe.
The CEO must ensure the organization has a clear governance framework for NPP operations in each market where it accepts named patient requests, including a documented policy on eligibility criteria, a defined process for physician request evaluation, and a country-specific understanding of the regulatory requirements.
Country-by-Country NPP Governance: The CEO’s Framework
The most important governance decision for named patient programs is the eligibility framework: under what circumstances will the company provide access to an investigational medicine outside of a clinical trial? This decision has clinical, ethical, legal, and commercial dimensions that require CEO involvement.
Key governance questions:
Stage of development. Most companies limit NPP access to medicines that have completed at least Phase 2 development and where the safety profile is reasonably characterized. Access to investigational medicines in Phase 1 development, where the safety database is small and dose optimization is incomplete, carries significant risk. The CEO should establish a development stage threshold for NPP eligibility.
Indication alignment. NPP access should generally be limited to the indication(s) for which the medicine is being developed. Access for non-development indications (essentially off-label compassionate use of an investigational medicine) creates clinical, regulatory, and liability risk that requires careful governance.
Clinical urgency criteria. Most NPP frameworks require that the patient has a serious condition, has exhausted available approved therapies, and cannot participate in a clinical trial. The CEO should ensure the company’s eligibility criteria for NPP access are clearly articulated and consistently applied.
Geographic scope. Companies with global development programs may receive NPP requests from markets where the drug is not being developed and where the company has no established presence. The CEO must decide the geographic scope of the NPP program and how out-of-scope requests are handled.
Supply chain allocation. NPP drug supply comes from the same manufacturing process as clinical trial supply. During Phase 3, when clinical trial supply demand is highest, NPP supply requests can create allocation conflicts. The CEO must ensure a clear framework for prioritizing clinical trial supply over NPP supply when conflicts arise.
For a framework on managing compassionate use program governance within the broader executive time architecture, see pharma CEO compassionate use management.
Safety Reporting from NPP: The Pharmacovigilance Obligation
Named patient programs generate safety data that pharmaceutical companies are legally obligated to include in their pharmacovigilance systems. Serious adverse events occurring in NPP patients must be collected, evaluated, and reported to regulatory agencies with the same rigor as adverse events from clinical trials.
The CEO’s pharmacovigilance governance responsibility for NPP:
Safety data collection systems. The NPP program must have mechanisms for collecting adverse event reports from prescribing physicians. In practice, this requires proactive follow-up: physicians who prescribe an investigational medicine to a named patient will not spontaneously submit adverse event reports unless prompted. The medical affairs team or the company’s pharmacovigilance team must maintain contact with prescribing physicians and actively collect safety information.
CIOMS and ICH E2A compliance. Serious unexpected adverse drug reactions in NPP patients must be reported to regulatory agencies in the markets where the events occur, under the same reporting timelines as IND/clinical trial adverse events (15 calendar days for fatal or life-threatening reactions; 7 days for fatal or immediately life-threatening reactions where the initial report is incomplete). The CEO must ensure the pharmacovigilance organization has the capacity to handle NPP safety reports within these timelines.
Integration into the aggregate safety database. NPP adverse events must be included in Periodic Safety Update Reports, Development Safety Update Reports, and other aggregate safety submissions. The CEO must ensure the pharmacovigilance organization has a structured process for integrating NPP safety data into the aggregate database.
Signal detection in NPP populations. NPP patients are often sicker, older, and more heavily pre-treated than clinical trial patients. They may experience adverse events that reflect their underlying disease or prior treatment rather than the investigational medicine. The CEO must ensure the pharmacovigilance organization has a clear framework for evaluating causality in NPP adverse event reports.
The EMA’s guideline on compassionate use of medicinal products provides the EU regulatory framework for pharmacovigilance obligations in compassionate use settings. CEOs should ensure the pharmacovigilance organization is familiar with and compliant with this guidance.
The Ethical Framework: Access and Equity
Named patient programs raise genuine ethical questions that the CEO must engage with directly. Who receives access when demand exceeds supply? How does the company balance the interests of individual patients seeking access with the interests of patients in clinical trials (whose data may be compromised if NPP patients are treated differently from trial patients)? How does the company respond to requests from markets where it does not have a regulatory presence and where the safety monitoring infrastructure is limited?
These are not questions with simple answers, but they require articulation of an ethical framework by the CEO rather than ad hoc case-by-case decision-making that creates inconsistent access and reputational risk.
Most companies address these questions through a formal NPP policy document that:
Establishes non-discrimination principles. Access decisions should be based on clinical criteria, not on patient financial resources, geography within the eligible markets, or prescribing physician relationship with the company.
Sets supply fairness mechanisms. When supply is limited, a fair allocation mechanism (first-approved, lottery, medical urgency ranking) should be articulated and consistently applied.
Defines geographic access boundaries. The policy should clearly define which markets are eligible for NPP access and why. Markets where the company cannot ensure adequate safety monitoring or where regulatory compliance is uncertain are legitimate grounds for geographic access limitations.
Addresses terminal illness and pediatric access. These are the cases where the ethical pressure for access is highest and where the risk-benefit framework may appropriately tilt more toward access than it would for less severe conditions.
Commercial Implications of NPP Programs
NPP programs have commercial dimensions that the CEO must acknowledge and manage, though they should not be the primary governance consideration. In markets where formal regulatory approval is pending, NPP access can generate pre-approval revenue in markets with government reimbursement for named patient supply (France’s ATU/Accès Précoce mechanism includes interim reimbursement, for example). NPP programs also generate real-world safety data and prescribing experience that can inform the post-approval commercial strategy.
The CEO must ensure that commercial considerations are appropriately subordinated to clinical and ethical ones in NPP governance. An NPP program designed primarily to generate pre-approval revenue, or to build prescriber relationships for commercial launch, rather than to provide access to patients with genuine unmet need, is misaligned with the purposes for which regulatory agencies authorize these programs and creates regulatory relationship risk.
Time Architecture for NPP Governance
A practical time architecture for pharma CEO named patient program time management:
Policy development and annual review. The CEO should personally approve the company’s NPP policy, covering eligibility criteria, geographic scope, supply allocation framework, and ethical principles. This policy should be reviewed annually and updated for any significant changes in the development program or regulatory environment.
Quarterly pharmacovigilance review. A quarterly review of NPP safety data, integrated with the broader pharmacovigilance program review, covering adverse event case volumes, serious adverse event rates, any notable signals, and regulatory reporting compliance status.
Supply allocation oversight. When NPP requests cannot be fully met due to supply constraints, the CEO should be notified of how the allocation framework is being applied and of any situations requiring escalation above the standard policy.
Regulatory authority interaction review. Quarterly review of any regulatory authority interactions related to NPP programs: ANSM requests, AIFA correspondence, MHRA queries. NPP regulatory authority interactions that suggest emerging regulatory concerns should be escalated to CEO attention.
Conclusion
Pharma CEO named patient program time management requires a CEO who understands that NPPs are a humanitarian and regulatory obligation, not a commercial opportunity. The governance framework the CEO establishes, covering eligibility criteria, safety reporting standards, ethical access principles, and geographic scope, determines whether the company’s NPP program serves its intended purpose and maintains the regulatory and community trust that all pharmaceutical programs require. The CEO who governs this program with integrity, who ensures safety data flows rigorously into the pharmacovigilance system, and who applies consistent, ethically grounded eligibility standards builds a corporate character that extends well beyond the NPP program itself.
Related Reading
For further context, explore How Pharma CEOs Balance Regulatory Affairs and Commercial Time and How Pharma CEOs Manage Time During Major Conference Season.